Cash rich start-ups are filing scores of patent claims on hallucinogens like magic mushrooms. Researchers and patient advocates worry high prices will make the therapies unaffordable.
With Promise of Legalization, Psychedelic Companies Joust Over Future Profits
The New York Times – Business:
This post first appeared in The New York Times – Business. Read the original article.
Written by
in